

Special Issue

Recent Advances in the Understanding of Myelodysplastic Syndrome and Acute Myeloid Leukemia

Message from the Guest Editors

During recent decades, significant progress has been made in the molecular characterization of myeloid malignancies, including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and myeloproliferative neoplasms (MPN). The technological progress made the identification of several driver mutations feasible, which paves the road for a personalized approach in the diagnosis and treatment of these disorders, as well as in the introduction of targeted therapies in the clinical practice. The aim of this Special Issue is to discuss recent findings in the epidemiology, treatment, and pathogenesis of MDS and AML. Epidemiological studies, clinical trials involving the introduction of novel treatment strategies in MDS and AML, original translational research articles and reviews are welcome in this Special Issue.

Guest Editors

Dr. Ioannis Mitroulis

Dr. Konstantinos Liapis

Dr. Eleni Gavriilaki

Deadline for manuscript submissions

closed (28 October 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/127123

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)